Durham-based Priovant Therapeutics, with Roivant Sciences, has shared encouraging results from its Phase 3 VALOR study evaluating brepocitinib, a potential new treatment for the autoimmune disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback